



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Alemtuzumab

Cat. No.:	HY-P9948
CAS No.:	216503-57-0
Target:	Apoptosis
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Alemtuzumab (Campath-1H) is a humanized monoclonal antibody against CD52. Alemtuzumab does not cross-react with murine CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. Alemtuzumab is capable of complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC), as well as induction of apoptosis. Alemtuzumab has the potential for B-cell chronic lymphocytic leukaemia research <sup>[1][2]</sup> .								
<b>In Vivo</b>	<p>Alemtuzumab (Campath-1H; 0.5-5 mg/kg; ip) with a single dose results in the dose-dependent depletion of B and T lymphocytes in the peripheral blood and lymphoid organs<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table><tr><td>Animal Model:</td><td>hCD52 transgenic mice<sup>[2]</sup></td></tr><tr><td>Dosage:</td><td>0.5-5 mg/kg</td></tr><tr><td>Administration:</td><td>IP; a single dose</td></tr><tr><td>Result:</td><td>Resulted in the dose-dependent depletion of B and T lymphocytes in the peripheral blood and lymphoid organs.</td></tr></table>	Animal Model:	hCD52 transgenic mice <sup>[2]</sup>	Dosage:	0.5-5 mg/kg	Administration:	IP; a single dose	Result:	Resulted in the dose-dependent depletion of B and T lymphocytes in the peripheral blood and lymphoid organs.
Animal Model:	hCD52 transgenic mice <sup>[2]</sup>								
Dosage:	0.5-5 mg/kg								
Administration:	IP; a single dose								
Result:	Resulted in the dose-dependent depletion of B and T lymphocytes in the peripheral blood and lymphoid organs.								

### REFERENCES

- [1]. Yanping Hu, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. *Immunology*. 2009 Oct;128(2):260-70.
- [2]. Kashani N, et al. Immune Regulatory Cell Bias Following Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis. *Front Immunol*. 2021;12:706278. Published 2021 Oct 28.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA